Alpha Teknova (TKNO) Q1 2025 Earnings Call May 08, 2025 05:00 PM ET Company Participants Jennifer Henry - Senior Vice President of MarketingStephen Gunstream - President & CEOMatthew Lowell - Chief Financial OfficerVidyun Bais - Equity Research - Vice PresidentChad Wiatrowski - VP - Equity Research Conference Call Participants Anna Snopkowski - Equity Research AnalystMatthew Hewitt - Senior Research AnalystMatt Larew - Research Analyst - Healthcare Operator Good day, and thank you for standing by. Welcome t ...

Financial Data and Key Metrics Changes - Total revenue for Q1 2025 was $155 million, with $138 million excluding license and royalty revenue, down 2% year over year [8][22] - Total consumables revenue was $115.4 million, up 5%, while instrument revenue was $14.8 million, down 42% [22][24] - Gross profit for Q1 was $105.4 million, with gross margins increasing to 68% from 66% year over year [25] - Operating loss for Q1 was $39.3 million, compared to a loss of $61.5 million in the same period last year [27] Business Line Data and Key Metrics Changes - Chromium consumables revenue was approximately flat at $84.1 million, while spatial consumables revenue increased by 18% to $31.2 million, driven by Xenium consumables [22][23] - Instrument revenue saw a significant decline, with Chromium instrument revenue down 25% and spatial instrument revenue down 49% [24][25] Market Data and Key Metrics Changes - Revenue in the Americas decreased by 7% to $73.8 million, EMEA decreased by 8% to $31.9 million, while APAC increased by 22% to $32.4 million [25] - Instrument revenue declined across all geographies, although strong consumable sales helped offset the impact in APAC [25] Company Strategy and Development Direction - The company is navigating a challenging macro environment, withdrawing full-year revenue guidance and implementing quarterly guidance due to uncertainty in U.S. academic and government research funding [12][29] - A reduction in workforce by approximately 8% has been implemented to enhance efficiency and protect the balance sheet [14][32] - The company is focused on product innovation and has seen increased usage of its products, particularly in single-cell and spatial biology [13][15] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to navigate current challenges and emphasized the importance of maintaining a strong balance sheet [12][14] - The macro environment has created uncertainty, leading to unpredictable customer purchasing behavior and reduced visibility on the outlook for the year [11][29] - Management remains optimistic about long-term growth potential despite current turbulence, citing strong fundamentals and customer engagement [21][39] Other Important Information - The company has completed a sales reorganization to better address current challenges and has a strong cash position of $427 million at the end of Q1 [14][27] - Recent product launches have resonated well with customers, contributing to the company's technology leadership [13][17] Q&A Session Summary Question: Can you provide insights on recent customer conversations and the impact of NIH funding? - Management noted that conversations with customers have become increasingly dire due to uncertainty around funding, prompting cost-cutting measures among institutions [44][45] Question: How do you expect the year to play out regarding instrumentation versus consumables? - Management indicated that Q2 is expected to mirror Q1 trends, with pressure on CapEx in instrumentation but stable consumables performance [54][55] Question: What are the implications of the headcount reduction on future growth? - Management stated that the headcount reduction was carefully considered, with minimal impact on direct sales roles, and emphasized the importance of retaining talent for future growth [66][67] Question: How is the company addressing potential tariffs and demand in China? - Management confirmed that there has been no pull forward in demand due to tariffs, and they are actively working on mitigation strategies to maintain production capabilities [100]

Financial Data and Key Metrics Changes - Total revenue for Q1 2025 was $155 million, with $138 million excluding license and royalty revenue, down 2% year over year [5][20] - Total consumables revenue was $115.4 million, up 5%, while instrument revenue was $14.8 million, down 42% [20][21] - Gross profit for Q1 was $105.4 million, with gross margins increasing to 68% from 66% year over year [22] Business Line Data and Key Metrics Changes - Chromium consumables revenue was approximately flat at $84.1 million, while spatial consumables revenue increased by 18% to $31.2 million, driven by Xenium consumables [20][21] - Total instrument revenue saw a significant decline, with Chromium instrument revenue down 25% and spatial instrument revenue down 49% [21] Market Data and Key Metrics Changes - Revenue in the Americas decreased by 7% to $73.8 million, EMEA decreased by 8% to $31.9 million, while APAC increased by 22% to $32.4 million [22] - Instrument revenue declined across all geographies, although strong consumable sales helped offset the impact in APAC [22] Company Strategy and Development Direction - The company is navigating a challenging macro environment, withdrawing full-year revenue guidance and implementing quarterly guidance due to uncertainty in U.S. academic and government research funding [10][25] - A focus on cost-saving measures, including an 8% reduction in workforce, is aimed at maintaining a strong balance sheet while continuing to invest in key priorities [12][29] - The company is committed to long-term growth, with confidence in capturing large opportunities despite current challenges [19][30] Management's Comments on Operating Environment and Future Outlook - Management highlighted a deteriorating research funding environment, with significant impacts on customer purchasing behavior and project initiation [9][10] - There is optimism regarding the long-term potential of the company's products, particularly in single-cell and spatial biology, despite current market challenges [11][19] - The company is closely monitoring the evolving tariff landscape, with minimal reliance on China in its supply chain [27][28] Other Important Information - The company has completed a sales reorganization to enhance focus and coverage in the current environment [11] - Recent product launches have been well-received, contributing to increased usage and adoption among customers [14][15] Q&A Session Summary Question: Current backdrop and customer conversations - Management noted that customer conversations have become increasingly dire due to funding uncertainties, prompting cost-cutting measures among institutions [42][44] Question: Year outlook and instrumentation vs consumables - Management indicated that Q2 is expected to mirror Q1 trends, with pressure on CapEx in instrumentation but stable consumables performance [55][56] Question: Headcount reduction and OpEx initiatives - The company emphasized that the headcount reduction will lead to over $50 million in operating expense savings for 2025, while still retaining critical talent for growth [70][69] Question: Regional sales dynamics - Management acknowledged that while EMEA sales have declined, the fundamental business remains strong, and recent hiring in Europe is expected to improve performance [76][75] Question: Demand in APAC and potential pull forward - Strong underlying demand in APAC, particularly in China and Japan, was noted, with structural improvements contributing to robust performance [78][79] Question: Long-term growth opportunities in organoid research - Management expressed optimism about the potential for single-cell sequencing in organoid research, viewing it as a promising growth area [99][98] Question: Tariffs and demand in China - The company does not anticipate significant pull forward in demand due to tariffs, and it has strategies in place to mitigate potential impacts [108][107]

Company Overview - Bio-Techne Corporation is a global life sciences company that provides innovative tools and bioactive reagents for research and clinical diagnostics [2] - The company generated approximately $1.2 billion in net sales in fiscal 2024 and employs over 3,100 people worldwide [2] Upcoming Events - Kim Kelderman, President and CEO of Bio-Techne, will present at the BofA Securities 2025 Health Care Conference on May 13, 2025, at 10:40 a.m. PDT [1]

Core Insights - Kennametal reported revenue of $486.4 million for the quarter ended March 2025, a year-over-year decline of 5.7% [1] - The EPS for the same period was $0.47, compared to $0.30 a year ago, indicating a significant increase [1] - The reported revenue fell short of the Zacks Consensus Estimate of $490.31 million, resulting in a surprise of -0.80% [1] - The company delivered an EPS surprise of +80.77%, with the consensus EPS estimate being $0.26 [1] Performance Metrics - Total Sales in the Infrastructure segment were $182.05 million, slightly below the average estimate of $183.52 million, reflecting a year-over-year change of -3.8% [4] - Total Sales in the Metal Cutting segment were $304.35 million, compared to the average estimate of $307.12 million, representing a year-over-year decline of -6.8% [4] - Operating Income (loss) for Corporate was -$0.26 million, better than the average estimate of -$0.69 million [4] - Proforma Operating Income for Infrastructure was $20.94 million, exceeding the average estimate of $12.93 million [4] - Proforma Operating Income for Metal Cutting was $29.22 million, surpassing the average estimate of $23.01 million [4] Stock Performance - Kennametal shares have returned +13% over the past month, outperforming the Zacks S&P 500 composite's +10.6% change [3] - The stock currently holds a Zacks Rank 4 (Sell), indicating potential underperformance relative to the broader market in the near term [3]

Bio-Techne (TECH) Q3 2025 Earnings Call May 07, 2025 09:00 AM ET Speaker0 Good morning, and welcome to Bio Techne Earnings Conference Call for the Third Quarter of Fiscal Year twenty twenty five. At this time, all participants have been placed in listen only mode, and the call will be opened for questions following the management's prepared remarks. During our Q and A session, please limit yourself to one question and a follow-up. I would now like to turn the call over to David Claire, Bio Vice President, I ...

Company Performance - Kennametal reported quarterly earnings of $0.47 per share, exceeding the Zacks Consensus Estimate of $0.26 per share, and up from $0.30 per share a year ago, representing an earnings surprise of 80.77% [1] - The company posted revenues of $486.4 million for the quarter ended March 2025, which missed the Zacks Consensus Estimate by 0.80% and decreased from year-ago revenues of $515.79 million [2] - Over the last four quarters, Kennametal has surpassed consensus EPS estimates three times and topped consensus revenue estimates two times [2] Stock Outlook - The stock has underperformed the market, losing about 17.5% since the beginning of the year compared to the S&P 500's decline of 4.7% [3] - The current consensus EPS estimate for the coming quarter is $0.37 on revenues of $520.2 million, and for the current fiscal year, it is $1.13 on revenues of $1.97 billion [7] - The estimate revisions trend for Kennametal is currently unfavorable, resulting in a Zacks Rank 4 (Sell) for the stock, indicating expected underperformance in the near future [6] Industry Context - The Manufacturing - Tools & Related Products industry, to which Kennametal belongs, is currently in the bottom 11% of over 250 Zacks industries, suggesting a challenging environment [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Kennametal's stock performance [5]

© 2025 Azenta, Inc. • All rights reserved 1 Conference Call Fiscal Second Quarter 2025 Financial Results May 7, 2025 1 Safe Harbor Statement "Safe Harbor" Statement under the U.S. Private Securities Litigation Reform Act of 1995; certain matters in this presentation, including forecasts of future demand and future Company performance, are forward-looking statements that are subject to risks and uncertainties that could cause actual results to materially differ, either better or worse, from those projected. ...

Standard BioTools (LAB) Q1 2025 Earnings Call May 06, 2025 04:30 PM ET Company Participants ​John Graziano - Vice President of Investor RelationsMichael Egholm - President & CEOAlex Kim - CFOPaul Knight - Managing Director Conference Call Participants Kyle Boucher - AnalystMatthew Stanton - Analyst Operator Please note this event is being recorded. I would now like to turn the conference over to John Graziano, Vice President of Investor Relations. Please go ahead. ​John Graziano Thank you, operator, and goo ...

Standard BioTools (LAB) Q1 2025 Earnings Call May 06, 2025 04:30 PM ET Speaker0 Please note this event is being recorded. I would now like to turn the conference over to John Graziano, Vice President of Investor Relations. Please go ahead. Speaker1 Thank you, operator, and good afternoon, everyone. Welcome to the Standard Bio Tools First Quarter twenty twenty five Earnings Conference Call. Leading the call today is Michael Egholm, President and Chief Executive Officer and Alex Kim, Chief Financial Officer. ...